Browse All

Current Filters

CLEAR FILTER x

TITLE

Opicapone as First-line Strategy for the Treatment of Wearing-off in Patients with Parkinson's Disease

Author:Ferreira, Joaquim   Lee, Jee-Young   Ma, Hyeo-il   Jeon, Beomseok   Poewe, Werner   Antonini, Angelo   Stocchi, Fabrizio   Rodrigues, Daniela   Fisher, Stanley   Fonseca, Miguel   Rocha, José-Francisco   Castilla-Fernández, Guillermo   Holenz, Joerg   Rascol, Olivier   

Session Name:P7: Movement Disorders: Parkinson's Disease Management  

Topic:Movement Disorders  

Program Number:P7.026  

Author Institution:IMM Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa  CNS-Campus Neurológico, Instituto De Medicin, Portugal  Department of Neurology, Seoul National University Hospital, Seoul, Korea, Republic of  Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria  University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy  Amneal Pharmaceuticals, Warren, NJ  Clinical Investigation Centre CIC1436 Departments of Neurosciences and Clinical Pharmacology, Centre of Excellence for Neurodegeneration COEN NeuroToul, and NS-Park/FCRIN network  University of Toulouse 3, University Hospital of Toulouse, INSERM, Toulouse, France  

Long-term Follow-up of Opicapone Use as Add-on to Levodopa in Parkinson’s Patients Without Motor Fluctuations: Findings from the EPSILON Study

Author:Ferreira, Joaquim   Rascol, Olivier   Stocchi, Fabrizio   Antonini, Angelo   Lapuente, Paloma   Castilla-Fernández, Guillermo   Brigas, Helena   Banisadr, Ghazal   Rocha, José-Francisco   Holenz, Joerg   Poewe, Werner   

Session Name:P7: Movement Disorders: Parkinson's Disease Management  

Topic:Movement Disorders  

Program Number:P7.027  

Author Institution:IMM Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa  CNS-Campus Neurológico, Instituto De Medicin, Portugal  Clinical Investigation Centre CIC1436 Departments of Neurosciences and Clinical Pharmacology, Centre of Excellence for Neurodegeneration COEN NeuroToul, and NS-Park/FCRIN network  University of Toulouse 3, University Hospital of Toulouse, INSERM, Toulouse, France  University San Raffaele Roma and Institute for Research and Medical Care IRCCS, Rome, Italy  BIAL – Portela & Ca S.A., CORONADO (S. Romão E S. Mamede, Portugal  Amneal Pharmaceuticals, Evanston, IL  Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria  

Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): QoL Results from a Phase 3 Randomized, Active-controlled Study

Author:Sarva, Harini   Tagliati, Michele   Poewe, Werner   Stocchi, Fabrizio   Rascol, Olivier   Yardeni, Tami   Lopes, Nelson   Pereira, Jonathan   Espay, Alberto   

Session Name:P11: Movement Disorders: Therapeutics in Study for Parkinson's Disease  

Topic:Movement Disorders  

Program Number:P11.007  

Author Institution:Weill Cornell Medical Center, New York, NY  Cedars-Sinai Medical Center, Movement Disorder Program, Los Angeles, CA  Department of Neurology, Medical University Innsbruck, Innsbruck, Austria  University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy  University of Toulouse 3, University Hospital of Toulouse, INSERM  Clinical Investigation Center CIC1436 Departments of Neurosciences and Clinical Pharmacology and NS-Park/FCRIN network, Toulouse, France  NeuroDerm Ltd. , Rehovot, Israel  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  James J and Joan A Gardner Center for Parkinson’s disease and Movement, University of Cincinnati, Cincinnati, OH